Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06002659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

Study acronym: CARMA-01
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2023 to May 1, 2024
    • Site details revised at 2 of 2 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
Trial Details
NCT Number NCT06002659
Lead Sponsor Uppsala University
Collaborators: Elicera Therapeutics, Uppsala University Hospital, Karolinska University Hospital
Conditions
(from sponsor)		 B-cell Lymphoma
Related terms Lymphoma, B-Cell
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov